2024
DOI: 10.1016/j.neurol.2024.06.003
|View full text |Cite
|
Sign up to set email alerts
|

Advocating for rituximab as first-line treatment for NMOSD-AQP4 patients in France: Cost and efficacy considerations

Romain Deschamps,
Caroline Papeix,
Xavier Ayrignac
et al.
Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 17 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?